KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Non-Current Liabilities: 2011-2024

Historic Total Non-Current Liabilities for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to $528.3 million.

  • Travere Therapeutics' Total Non-Current Liabilities fell 11.47% to $459.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $459.1 million, marking a year-over-year decrease of 11.47%. This contributed to the annual value of $528.3 million for FY2024, which is 8.57% down from last year.
  • Latest data reveals that Travere Therapeutics reported Total Non-Current Liabilities of $528.3 million as of FY2024, which was down 8.57% from $577.8 million recorded in FY2023.
  • Travere Therapeutics' Total Non-Current Liabilities' 5-year high stood at $620.3 million during FY2022, with a 5-year trough of $331.1 million in FY2020.
  • In the last 3 years, Travere Therapeutics' Total Non-Current Liabilities had a median value of $577.8 million in 2023 and averaged $575.5 million.
  • As far as peak fluctuations go, Travere Therapeutics' Total Non-Current Liabilities declined by 8.71% in 2020, and later soared by 52.26% in 2022.
  • Over the past 5 years, Travere Therapeutics' Total Non-Current Liabilities (Yearly) stood at $331.1 million in 2020, then increased by 23.04% to $407.4 million in 2021, then surged by 52.26% to $620.3 million in 2022, then decreased by 6.86% to $577.8 million in 2023, then declined by 8.57% to $528.3 million in 2024.